Skip to main content
Clinical Trials/CTRI/2020/07/026362
CTRI/2020/07/026362
Not Yet Recruiting
N/A

CLINICAL EVALUATION OF THE THERAPEUTIC EFFICACY OF SARVAKALPA-GHAN-VATI IN NON-ALCOHOLIC LIVER DISORDER.

Patanjali Research Institute0 sites0 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Health Condition 1: K77- Liver disorders in diseases classified elsewhere
Sponsor
Patanjali Research Institute
Status
Not Yet Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\)Patients between the age group of 18\-65 years will be selected.
  • 2\)Patients irrespective of sex, religion, occupation and chronicity will be selected for the study.
  • 3\)Both fresh and treated cases would be taken for the study.
  • 4\)Patients with higher LFT levels than the upper limit of normal value will be selected.
  • 5\)Patients with GRADE 1 and GRADE 2 fatty liver will be selected for the study.
  • 6\)Patient with controlled Diabetes mellitus having GRADE 1 and GRADE 2 fatty liver will be selected for the study.

Exclusion Criteria

  • 1\)Patients aged \<18 years or \>65 years will be excluded.
  • 2\)Pregnant or lactating women will be excluded.
  • 3\)Patients who had hepatitis B, C or other hepatic viral infection, autoimmune hepatitis and drug\-induced hepatitis or alcoholic hepatitis will be excluded.
  • 4\)Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded.
  • 5\)Patients will be excluded having decompensated liver disease.
  • 6\)Patients with prolonged or a history of ascites, developed hepato\-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded.
  • 7\)Patients with a history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded.
  • 8\)Patients having GRADE 3 fatty liver disease will be excluded

Outcomes

Primary Outcomes

Not specified

Similar Trials